# Study to Evaluate Safety, Tolerability and Efficacy of Oral E-B-FAHF-2 in Mild-to-Moderate Crohn's Disease

> **NCT03992469** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 7 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** EBFAHF-2
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03992469
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-15
- **Primary completion:** 2026-02-02
- **Final completion:** 2026-02-02
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2025-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03992469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03992469, "Study to Evaluate Safety, Tolerability and Efficacy of Oral E-B-FAHF-2 in Mild-to-Moderate Crohn's Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03992469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*